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Abstract
A role for microbes has been suspected in prostate cancer but difficult to confirm in human patients. We show here
that a gastrointestinal (GI) tract bacterial infection is sufficient to enhance prostate intraepithelial neoplasia (PIN) and
microinvasive carcinoma in a mouse model. We found that animals with a genetic predilection for dysregulation of
wnt signaling, ApcMin/+ mutant mice, were significantly susceptible to prostate cancer in an inflammation-dependent
manner following infection with Helicobacter hepaticus. Further, early neoplasia observed in infected ApcMin/+ mice
was transmissible to uninfected mice by intraperitoneal injection of mesenteric lymph node (MLN) cells alone from H.
hepaticus-infected mutant mice. Transmissibility of neoplasia was preventable by prior neutralization of inflammation
using anti-TNF-α antibody in infected MLN donor mice. Taken together, these data confirm that systemic
inflammation triggered by GI tract bacteria plays a pivotal role in tumorigenesis of the prostate gland.
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Introduction
Only a small proportion of dysplastic and early neoplastic
lesions arising in epithelia throughout the body actually
advance into cancer [1–3]. Cancer happens when cells with
malignant potential achieve all stimuli needed for their genetic
and epigenetic evolution into malignancy [4]. It is now well
documented that for many types of cancer a major contributor
is cells and factors of the immune system [4–6]. In the prostate
gland, several lines of evidence suggest that chronic
inflammation drives the prostate cancer process [5,7,8], but its
source remains elusive. Infectious agents, chemical or physical
epithelial cell injury, hormonal imbalances and dietary factors
have been proposed as the most probable causes of chronic
inflammation in the prostate [8–10].
Determining whether prostate malignancy may be
preventable by targeting underlying inflammation has particular
importance since it is a leading cause of cancer-related
disability and death among men. In the gastrointestinal (GI)
tract, infections with pathogenic microbes, such as with
Helicobacter pylori, lead to chronic inflammation (gastritis) and
cancer (gastric adenocarcinoma) in humans and in mouse
models [4]. Likewise, in immunocompromised mouse models
the related lower bowel bacterium Helicobacter hepaticus (H.
hepaticus) triggers inflammatory bowel disease (IBD) and
colorectal carcinoma (CRC) [11–13]. In the prostate gland,
however, few animal models exist to test possible direct or
even indirect roles of pathogenic microbes in prostate
malignancy [8,10,14].
In humans, the adenomatosis polyposis coli (Apc) gene is a
critical tumor suppressor gene that prevents malignancy of
prostate and other tissues [15]. Here, we use mutant mice that
lack one copy of the Apc gene (ApcMin/+ mice) and exhibit
dysregulation of β-catenin and the wnt signaling pathway and
are otherwise extensively used as a model of intestinal
adenomas [16]. ApcMin/+ mice spontaneously develop prostate
intraepithelial neoplasia (PIN) and microinvasive carcinoma
(microinvasive CA) with increasing age, mimicking the initial
stages of prostate cancer seen in humans in their fifth or sixth
decade of life [15,17]. We show that orogastric dosing with H.
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hepaticus, a non-colitigenic for this mouse model bacterial
bowel colonizer [17], significantly increases prostate cancer.
Importantly, development of prostate cancer was transmissible
to uninfected animals solely by transfer of mesenteric lymph
node cells from H. hepaticus-infected ApcMin/+ donor mice.
Results
Orogastric infection with Helicobacter hepaticus
increases risk of prostate carcinoma in male ApcMin/+
mice
To determine the impact of intestinal infection, we used
ApcMin/+ mice that were cancer-free (young mice at age of 12
weeks had no prostate carcinoma or intestinal polyps) [17].
Mice were orally dosed with H. hepaticus or underwent sham
dosing with media at six weeks of age. By 12 weeks of age,
ApcMin/+ mice infected with H. hepaticus displayed features of
prostate carcinoma consistent with those observed in human
males (Figure 1A, 1B; Table S1). H. hepaticus-infected ApcMin/+
mice exhibited increased PIN (p<0.01) and microadenoCA
(p<0.01) when compared with sham-dosed matched uninfected
control ApcMin/+ mice (Figure 1C and S1). Neither H. hepaticus-
infected nor uninfected 12-week-old wt mice exhibited
significant prostate pathology. Together these results
demonstrate that infection of the GI tract with H. hepaticus
rapidly enhances prostate carcinogenesis in genetically
susceptible mice.
Elevations of inflammatory cytokines occur without
overt inflammatory disease in H. hepaticus–infected
ApcMin/+ mice
We next tested whether H. hepaticus infection leads to
increased inflammatory responses as previously shown [13].
We found that H. hepaticus-infected ApcMin/+ mice exhibited
increased systemic pro-inflammatory cytokines including tumor
necrosis factor (TNF)-α (p=0.013), IL-1α (p=0.024), IL-3
(p=0.0009) and eotaxin (p=0.003) (Figure 2A left). Interestingly,
prostates from H hepaticus-infected ApcMin/+ mice lacked overt
inflammatory disease but exhibited occasional mast cells,
neutrophils, and also myeloid precursor cells bearing ring-
shaped nuclei [18] (Figure 1D).
Neutralization of inflammation inhibits H. hepaticus–
induced prostate carcinoma in male ApcMin/+ mice
Pro-inflammatory cytokine TNF-α was found to be elevated
(p= 0.013) in sera after H. hepaticus infection for six weeks in
three-month-old male ApcMin/+ mice (Figure 2A). TNF-α is at the
apex of a cascade of carcinogenic pro-inflammatory events [5].
To test whether inflammation is required for GI tract bacteria-
triggered prostate pathology, we performed systemic
neutralization of TNF-α using intraperitoneal injection of anti-
TNF-α antibody for 3 weeks duration starting at 3 weeks post-
infection (PI). We found that anti-TNF-α treatment led to
significantly less (p<0.01) prostate pathology in H. hepaticus-
infected ApcMin/+ mice (Figure 1A, 1C and S1; Table S1). Taken
together with earlier data, this indicated that H. hepaticus-
triggered host inflammatory responses enhanced neoplastic
effects in prostate tissue.
Inflammatory cytokines were elevated in H. hepaticus-
infected ApcMin/+ mice but not in H. hepaticus-infected
wt littermate mice
A feature of this mouse model is that H. hepaticus-infected
ApcMin/+ mice displayed significantly increased high grade PIN
(HGPIN) and prostate carcinoma; however, matched H.
hepaticus-infected wt littermate mice fail to develop significant
PIN or carcinoma lesions (Figure 1B, 1C and S1, Table S1).
Upon analysis of serum cytokine levels, we discovered
significant differences in protein levels of IL-1α (p=0.02) and
IL-17 (p=0.0005) between ApcMin/+ and the wt littermate mice
(Figure 2A right). Likewise, in situ labeling of IL-17 showed
increased IL-17+ expression levels in MLN in H. hepaticus-
infected ApcMin/+ mice but not in the H. hepaticus-infected wt
controls (Figure 2B and 2C). Treatment of H. hepaticus-
infected ApcMin/+ mice with anti-TNF-a antibody significantly
decreased mRNA gene expression (p<0.01) and protein
(p<0.001) levels of IL-17A in MLN (Figure 2B and 2C). Taken
together, these accumulated data raised the possibility that
systemic differences originating from bacteria-triggered
inflammation of GI tract origin may contribute to carcinogenic
processes in distant tissues such as prostate.
Prostate cancer risk is transmissible to uninfected
recipients using mesenteric lymph node (MLN) cells
from H. hepaticus-infected ApcMin/+ mice
Knowing that GI tract origin inflammatory response is
necessary for prostate cancer in our model, we hypothesized
that cells within gut-associated lymph nodes (MLN) may be
pivotal in prostate cancer in this model. In order to test this
hypothesis, we utilized cell transfer of MLN collected from H.
hepaticus-infected or sham-dosed donor ApcMin/+ or wt
littermate mice (Figure 3). For this experiment, all recipient
animals were Helicobacter sp-free male ApcMin/+ or wt
littermates. Male mice of age 6-8 weeks underwent ip injection
of 5X106 single cell suspension in HBSS per mouse of cells
gathered from mesenteric lymph nodes of H. hepaticus-
infected or sham-dosed ApcMin/+ or wt mice.
Consequently, we found significantly increased low (p<0.05)
and high grade (p<0.01) PIN in uninfected ApcMin/+ mice that
had merely received MLN cells from H. hepaticus-infected
ApcMin/+ mice (Figure 1A, B, C and S1) at 6 weeks after ip
injection, when compared with MLN donor cells from sham-
dosed ApcMin/+ mice. These uninfected ApcMin/+ that received
cells from H. hepaticus-infected ApcMin/+ displayed features of
preneoplasia and carcinoma consistent with those observed in
H. hepaticus-infected ApcMin/+ mice (Figure 1A), and resembling
those seen in human males. In addition, uninfected wt recipient
mice that received lymph node cells from H. hepaticus-infected
ApcMin/+ donor mice also had increased LGPIN (p<0.001),
HGPIN (p<0.001) and adenocarcinoma (p<0.001) (Figure 1C
and S1; Table S1) compared to uninfected wt mice that
received lymph node cells from H. hepaticus-free ApcMin/+ donor
mice showing that genetic predisposition of prostate epithelia
was not specifically required for carcinogenic effect of H.
Intestinal bacteria and prostate cancer
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Figure 1.  Clinically silent immune system alterations affect dorsolateral prostate (DLP) carcinogenesis in B6 ApcMin/+
mice after GI infection with H. hepaticus.  A) By the age of 12 weeks, ApcMin/+ mice spontaneously develop focal low and high
grade prostate intraepithelial neoplasia (LGPIN, white arrow-head; HGPIN, black arrow-head) but only rare microinvasive carcinoma
(a). Aged-matched ApcMin/+ mice with H. hepaticus, develop significantly more PIN and microinvasiveCA lesions (asterisk)
characterized by highly atypical prostate gland epithelial cells which break through the basal lamina and infiltrate the adjacent
stroma (b). When mesenteric lymph node cells from H. hepaticus-infected ApcMin/+ mice are transferred into the peritoneal cavity of
H. hepaticus-free ApcMin/+ mice the recipient mice develop preneoplastic and early neoplastic lesions (microinvasiveCA-asterisk)
comparable to those found in donor mice (c). Depleting TNF- α from H. hepaticus-infected ApcMin/+ mice brings prostate neoplastic
lesions (LGPIN, white arrow-head) occurrence to the level of H. hepaticus-free mice (d). Hematoxylin and Eosin. Bars=50 μm. B)
Aberrant β-catenin and laminin immunostaining pattern in microinvasiveCA lesions in prostate cancer. DLP from WT H. hepaticus-
positive mice (a and c), H. hepaticus-infected ApcMin/+ mouse (b) and H. hepaticus-free ApcMin/+ mouse transferred with mesenteric
lymph node cells from H. hepaticus-infected ApcMin/+ donor (d). Normal DLP glands had a normal β-catenin lateral epithelial cell
membrane staining pattern (a) and an intact basal lamina (c). In contrast, microinvasiveCA lesions were characterized by
cytoplasmic and nuclear (arrow-heads) stabilization of β-catenin (b) and absence of laminin (asterisk) suggestive of basal
membrane degradation in malignant epithelial cell foci of incipient invasion. Hematoxylin counterstain, DAB chromogen. Bars=25
μm. C) Bar graph showing frequency of PIN and microinvasiveCA in treatment groups. The most significantly elevated prostate
cancer occurrence is denoted by asterisk. Standard error bars correspond to microinvasiveCA statistical comparisons. D) DLP of H.
hepaticus-free ApcMin/+ mouse transferred with MLN cells from a H. hepaticus-infected ApcMin/+ donor, HGPIN. Most myeloid
precursor cells with ring-shaped nuclei residing in the stroma have the typical granulocytic lineage phenotype (black arrow-head)
while fewer appear to be myelo/monocytic in type (white arrow-head). Bar=16 μm.
doi: 10.1371/journal.pone.0073933.g001
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Figure 2.  Intestinal H. hepaticus infection triggers systemic elevations in pro-inflammatory cytokines.  A) Serum levels of
pro-inflammatory cytokines were increased in ApcMin/+ mice after H. hepaticus infection. Eotaxin, IL-3, TNF-α and IL-1α were
significantly elevated in comparison with age-matched uninfected ApcMin/+ controls. When compared with H. hepaticus infected wt
mice, infected ApcMin/+ mice had significantly higher IL-17, IL-1α, IL-3, eotaxin and IL-9 concentration in their blood serum. Bio-Plex
Cytokine Assay used sera of n=5 mice per group. ***p<0.001; *p<0.05. B) Paracortical areas in mesenteric lymph nodes. H.
hepaticus infected ApcMin/+ mice at high risk of prostate cancer had large amounts of cytoplasmic and extracellular IL-17 that
significantly decreased after depletion of TNF-α. IL-17-specific immunohistochemistry; Hematoxylin counterstain, DAB chromogen.
Bars=25 μm. C) Morphometric assessment of IL-17 in immunohistochemically stained sections of mesenteric lymph nodes. Both
ApcMin/+ genetic status and intestinal infection by H. hepaticus significantly correlate with a TNF-α-mediated increase of IL-17
expression in the mesenteric lymph nodes. ***p<0.001; **p<0.01; *p<0.05.
doi: 10.1371/journal.pone.0073933.g002
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hepaticus infection. This transmissibility feature showed that H.
hepaticus-activated cells were sufficient for neoplastic
processes in extra-intestinal glands such as prostate.
Neutralization of inflammation prevents MLN cell
transmissibility of prostate cancer risk to uninfected
mice
Finally, we tested whether neutralizing inflammation was
sufficient to inhibit MLN-cell mediated transmissibility of
prostate cancer in this mouse model. We utilized cell transfer of
MLN collected from H. hepaticus-infected ApcMin/+ mice that had
been treated with anti-TNF-a antibody for 3 weeks (Figure 3).
For this experiment, all recipient animals were Helicobacter sp-
free male ApcMin/+ or wt littermate animals. Male mice of age 6-8
weeks underwent ip injection of 5X106 single cell suspension in
HBSS per mouse of cells gathered from mesenteric lymph
nodes of H. hepaticus-infected ApcMin/+ mice. As predicted, we
found no significant differences between uninfected ApcMin/+
mice vs uninfected ApcMin/+ mice that had received MLN from
anti-TNF-α-treated mice (p>0.05). Likewise, there was
significantly less LGPIN (p<0.01) and HGPIN (p<0.05) in
uninfected ApcMin/+ recipients of MLN from anti-TNF-treated H.
hepaticus-infected mice when compared with ApcMin/+ recipient
Figure 3.  Transfer of mesenteric lymph node (MLN) cells from H hepaticus-infected mice is sufficient to recapitulate
prostate cancer in uninfected mice.  Schematic illustration of MLN cells transfer experiments designed to test the hypothesis that
local GI tract immune network events cause systematic immune imbalances that determine the fate of preneoplastic lesions in
topographically distant epithelia such as those of the prostate gland. Trials used 6 mice per group. Experiments were done in
duplicate.
doi: 10.1371/journal.pone.0073933.g003
Intestinal bacteria and prostate cancer
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mice of MLN from H. hepaticus-infected ApcMin/+ mice (Figure
1C and S1; Table S1). These data indicate that the pro-
inflammatory role of the MLN cells is the underlying cause of
the observed prostate cancer risk transmissibility.
Discussion
In the present study, we test young male ApcMin/+ mice on a
C57BL/6J background as an experimental model to probe
associations of inflammation with carcinogenesis in the
prostate. As with humans where prostate cancer risk has a
strong genetic component, ApcMin/+ mutant mice are genetically
predisposed to epithelial neoplasia [13,16,17]. We and others
have shown in the past that ApcMin/+ mice also progressively
develop prostate cancer on the basis of increased PIN lesions
matching that seen in human males [15,17]. In our studies,
ApcMin/+ mice develop early neoplastic lesions in the
dorsolateral prostate as early as at 3 months of age preceding
evident intestinal polyps. At age = 6 months, 40% of ApcMin/+
mice develop microinvasive adenocarcinoma while 10-20%
also have more advanced prostate cancer lesions [15]. This
aspect gives the ApcMin/+ mouse utility as a model to examine
progression of pre-neoplastic and early neoplastic lesions in
the human prostate [1–3].
An important finding of this study is that infection with H.
hepaticus, a bacterium that colonizes primarily the large
intestine of C57BL/6 ApcMin/+mice without overt typhlocolitis
[13,19–21], significantly increased the incidence of PIN and
microinvasive adenocarcinoma lesions in the prostate. As
expected, 3-months-old ApcMin/+ mice infected with H. hepaticus
had neither overt IBD nor large adenomatous polyps yet
formed in their bowels (data not shown). However, even at this
young age, these mice did exhibit increased systemic pro-
inflammatory cytokines, such as TNF-α, IL-1α, IL-3, eotaxin
and IL-9, compared to their uninfected control counterparts,
indicative of immune system activation. These data taken
together with previous evidence that H. hepaticus infection is
able to modulate tumorigenesis at extra-intestinal sites [21,22],
suggest that clinically silent GI tract immune network events
triggered by gut microbiota may cause systematic immune
imbalances. In turn, these imbalances may impact the fate of
preneoplastic lesions in topographically distant epithelia such
as those of the prostate gland.
The interrelated roles of the elevated proinflammatory
cytokine milieu and the inflammatory cellular component found
in the prostate cancer prone H. hepaticus-infected ApcMin/+ mice
are interesting. Within the prostate gland, PIN and
microinvasive adenocarcinoma featured mast cells,
neutrophils, and myeloid precursor cells bearing ring-shaped
nuclei. TNF-α was previously proven essential in mast cell
recruitment and tumorigenesis in ApcMin/+ mice [13,17,23]. The
release of factors including TNF-α and various proteases from
mast cells residing in the prostate stroma may have an
important role in tumorigenesis [10].
TNF-α and IL-1α have been together implicated in a NF-κB-
mediated signal cascade that inhibited apoptosis and increased
the proliferation of epithelial cells in human prostate
preneoplasia and cancer [24]. In addition, IL-1α promotes the
abnormal proliferation of human prostate epithelial cells
through insulin growth factor- and fibroblast growth factor-7-
related growth signals [25,26]. Eotaxin and IL-3 regulate bone
marrow maturation, release and tissue trafficking of myeloid
precursor cells [27] such as those seen in prostate glands of H.
hepaticus-infected ApcMin/+ mice. Potential roles of eotaxin, IL-3
and associated myeloid precursor cells in epithelial
carcinogenesis warrant further investigation. The powerful pro-
inflammatory role of IL-9 is increasingly appreciated. Th9 cells
constitute the latest addition expanding the T-helper subtype
array. IL-9 stimulates the growth of hematopoietic cells,
especially mast cells and the secretion of several chemokines
that recruit additional cells to inflamed tissues [28]. The
important role of IL-9 in autoimmunity and allergy [28] may
provide important clues, especially in the light of recent
hypotheses that connect prostate inflammation with cancer.
Prostate epithelial cell injury may then cause loss of tolerance
to normal prostatic antigens and consequently lead to a self-
perpetuating autoimmune reaction [10]. In the present study,
our finding that neutralization of TNF-α was sufficient to
counteract prostate cancer risk enhancement in a mouse
model suggests that this cytokine has a central role in creating
a pro-tumorigenic systematic inflammatory macro-environment
that allows the progression of cancer in the prostate gland.
Another pro-inflammatory cytokine we found significantly
elevated by comparing H. hepaticus-infected ApcMin/+ mice with
H. hepaticus-infected wt littermate mice was Il-17A. The
significant differences in Il-17 were of particular interest
because we have previously shown IL-17+ cells in mesenteric
lymph node (MLN) of mice after infection with H. hepaticus
[20]. Likewise, IL-17 has been implicated in infection-triggered
bowel cancer development in ApcMin/+ mice [29,30]. The
correlation of the ApcMin/+ mouse genotype with systematic and
MLN elevations in Il-17 expression may have a genetic basis,
since Il-17-associated deficits in the immune cell function of
this mouse model have been reported [30]. Importantly, recent
evidence from both preclinical mouse [31] and clinical human
studies support a significant role for Il-17 in prostate
carcinogenesis [32,33].
To provide experimental proof for this hypothesis and retain
the complex immunological interplay of the various cell
populations we chose to transfer total MLN cell populations into
mice. Immunological activities within systemic lymph node
tissue [20] may be the link connecting GI microbial flora with
universally pro-tumorigenic systematic alterations of the
immune system. Surprisingly, we found that increased prostate
cancer risk is transmissible to uninfected ApcMin/+ recipients of
MLN cells only taken from H. hepaticus-infected ApcMin/+
donors. There was no evidence of H. hepaticus organisms in
prostate tissue of transplant recipient mice using PCR or by in
situ examination using silver stain (data not shown), but
translocation of H. hepaticus organisms or their antigens from
intestines to lymph nodes remain a possible contributing factor.
Our finding that MLN cells taken from anti-TNFα-treated H.
hepaticus-infected ApcMin/+ lost the prostate cancer promoting
effects provides evidence that inflammation enhanced this
carcinogenic process.
Intestinal bacteria and prostate cancer
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In conclusion, a possible role for microbes in prostate
malignancy has been suspected [9] but remained unproven
until now. Here we have demonstrated that ingestion of H.
hepaticus alone enhanced prostate carcinogenesis in ApcMin/+
mice. Our finding that inflammation enhanced this cancer
forming process adds mechanistic support to the well-
documented benefits of non-steroidal anti-inflammatory drugs
(NSAIDs) in human patients. Remarkably, uninfected mice that
received only lymph node cells became highly susceptible to
prostate cancer. This observation that prostate cancer is
inducible by distilled cells from another organ may help explain
why etiopathogenesis of prostate cancer in humans has been
difficult to elucidate. It remains to be definitely determined
whether other GI tract microbes in humans, such as H pylori,
may have a similar effects in prostate and other non-
gastrointestinal cancers of humans.
Materials and Methods
Experimental animals
All animals were housed and handled in Association for
Assessment and Accreditation of Laboratory Animal Care
(AAALAC)-accredited facilities with diets, experimental
methods, and housing as specifically approved by the
Institutional Animal Care and Use Committee. The MIT CAC
(IACUC) specifically approved the studies as well as the
housing and handling of these animals. ApcMin/+ mice on a
C57BL/6J background were originally obtained from the
Jackson labs and bred in-house to provide ApcMin/+ mice and
wildtype (wt) littermates for experimental recipients and donors.
Helicobacter-free status of the mice was confirmed by PCR
using Helicobacter genus-specific primers as previously
described [20].
Experimental Helicobacter hepaticus infection
A total of 44 experimental mice were dosed at 6 weeks of
age with H. hepaticus (strain 3B1, ATCC #51449) and then
housed separately in a bio-containment area within the same
animal facility. H. hepaticus was grown under microaerobic
conditions, prepared, and confirmed pure as described
elsewhere [11,20]. Experimental mice received 0.2ml of fresh
inoculum by gastric gavage every other day for a total of three
doses. Cecum, mesenteric lymph node (MLN), and prostate
were collected 6 weeks post-infection at necropsy and
analyzed by PCR to confirm (bowel) or exclude (MLN, prostate)
colonization.
Experimental design
A total of 96 ApcMin/+ mice and 60 wt mice were included in
various treatment regimens or as experimental controls.
Experiments were conducted using two separate trials with 5-6
mice each, as specified in Table S1. Sixty ApcMin/+ mice and 40
wt mice age of 6 weeks were injected intraperitoneally with 5 x
106 MLN cells suspended in HBSS. The cell donor mice were
male H. hepaticus-infected six weeks earlier, or Helicobacter-
free C57BL/6 wt or ApcMin/+ mice.
TNF-α neutralization
A total of 24 H. hepaticus infected ApcMin/+ or wt mice at age
of 9 weeks (starting at 3 weeks after H. hepaticus infection)
received anti-TNF-α antibody (clone XT-3; BioExpress,
Lebanon, NH) at 200µg per mouse three times weekly for three
weeks as described previously [13].
Detection of systemic cytokine protein expression
Serum cytokine levels of 5-6 animals in each experimental
group were analyzed using the Bioplex Pro Mouse Cytokine
assay system (BioRad, Hercules, CA) according to the
manufacturers protocol. Briefly, serum samples were diluted
using the sample diluent kit, incubated with antibody coated
beads followed by a secondary antibody incubation and
analyzed in duplicates on a Bio-Plex 200 system (BioRad,
Hercules, CA).
Histologic evaluation and Immunohistochemistry
The formalin-fixed tissues were processed and paraffin
embedded 5µm tissue-sections were stained by H&E, Warthin-
Starry silver stain or IHC and evaluated for prostate lesions by
a veterinary pathologist blinded to sample identity. The
preneoplastic and early neoplastic prostate lesions, detected
based on recent consensus report criteria [34], were
quantitatively assessed as described previously by Poutahidis
et al (2009) [17].
Rabbit primary antibodies used for immunohistochemistry
included anti-β-catenin (Thermo, Fisher Scientific/Lab Vision,
Fremont, CA), anti-laminin (Thermo, Fisher Scientific/Lab
Vision, Fremont, CA) and anti-IL17 (Santa Cruz Biotechnology,
Santa Cruz, CA). Antigens were retrieved with Protease 1
(Roche Diagnostics/Ventana Medical Systems, Tucson, AZ) for
laminin detection. Heat-induced antigen retrieval was
performed with citrate buffer pH6 for β-catenin or with EDTA
buffer pH8 for IL17 detection. Primary antibody binding was
detected with goat anti-rabbit Zytochem Plus HRP Polymer
(Zytomed Systems, Berlin, Germany). Signal was detected with
diaminobenzidine (Invitrogen, Camarillo, CA) and tissues were
counterstained with hematoxylin.
For the quantification of IL-17 expression in MLN, thirty 40x
high power field images of IHC-stained sections were captured
per treatment group. Ten images from each group were
randomly selected for counts. Automatic calculation of the
numbers of pixels corresponding to IL-17 in images appeared
in a histogram after processing each image with the threshold
color plug-in of the ImageJ image processing and analysis
program (NIH, Bethesda, MD). Morphometric counts were
recorded as the number of IHC labeled pixels per image.
Statistical analyses
The prevalence of LGPIN, HGPIN and micro-adenoCa
between groups was compared by the Kruskal-Wallis one-way
ANOVA and Dunn’s post-test. Direct comparisons were made
by the Mann–Whitney U test. Serum cytokine data analysis
was performed using the 2-tailed student’s t-test. IL-17
immunohistochemically-positive image pixel count data were
evaluated for normality with Shapiro-Wilk test and analyzed
Intestinal bacteria and prostate cancer
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with one way analysis of variance (ANOVA) and Tukey’s
multiple comparison post test. Statistical analyses were
performed with Graphpad Prism version 5.0 for Windows,
GraphPad software, San Diego, CA, USA; a p-value < 0.05
was considered statistically significant.
Supporting Information
Figure S1.  Statistical analyses of prostate pathology in
treatment groups. Treatment groups match those portrayed in
Figure 1. ***p<0.001; **p<0.01; *p<0.05.
(TIF)
Table S1.  Frequency of prostate pathology types within
treatment groups.
(DOC)
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